BUCHAN JANE 4
4 · Immix Biopharma, Inc. · Filed May 20, 2024
Insider Transaction Report
Form 4
BUCHAN MELISSA JANE
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-05-15+24,153→ 24,153 totalExercise: $2.47Exp: 2033-05-26→ Common Stock (24,153 underlying) - Award
Common Stock
2024-05-20+1,127→ 22,455 total - Award
Stock Option (Right to Buy)
2024-05-15+20,436→ 20,436 totalExercise: $2.47From: 2024-05-15Exp: 2033-05-26→ Common Stock (20,436 underlying) - Award
Common Stock
2024-05-15+1,332→ 21,332 total
Footnotes (4)
- [F1]Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024.
- [F2]Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.
- [F3]Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity.
- [F4]The Stock Option will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.